The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.

Title
Inhibitors of Serine Proteases
Application Number
12/528952
Publication Number
20100272681
Application Date
February 20, 2008
Publication Date
October 28, 2010
Inventor
Summer Halas
Somerville
MA, US
Kevin Cottrell
Cambridge
MA, US
John Maxwell
Quincy
MA, US
Robert B Perni
Marlborough
MA, US
Dylan Jacobs
Boston
MA, US
Randy Scott Bethiel
Lexington
MA, US
Luc Farmer
Foxborough
MA, US
Agent
Honigman Miller Schwartz & Cohn
MI, US
Agent
Jonathan P O Brien PhD
MI, US
Assignee
Vertex Pharmaceuticals Incorporated
MA, US
IPC
A61K 38/00
A61P 31/12
A61K 31/427
A61K 31/42
A61K 31/422
A61K 31/40
C07D 498/10
C07D 487/10
A61K 38/21
View Original Source